Patents by Inventor Claire Louise Kulisa

Claire Louise Kulisa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutically active oxazoline derivatives
    Patent number: 9382263
    Abstract: Compounds of formula (I) i.e. monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives substituted by an optionally substituted oxazolin-2-yl moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: July 5, 2016
    Assignee: UCB Biopharma SPRL
    Inventors: Claire Louise Kulisa, Daniel Christopher Brookings, Daniel James Ford, Richard Jeremy Franklin, James Thomas Reuberson, Anant Ramrao Ghawalkar
  • Therapeutically active fused pyrimidine derivatives
    Patent number: 9227984
    Abstract: A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: January 5, 2016
    Assignees: UCB Pharma S.A., Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Daniel Christopher Brookings, Daniel James Ford, Anant Ramrao Ghawalkar, Jean Herman, Qiuya Huang, Claire Louise Kulisa, Thierry Louat, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Therapeutically Active Oxazoline Derivatives
    Publication number: 20150274748
    Abstract: Compounds of formula (I) i.e. monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives substituted by an optionally substituted oxazolin-2-yl moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.
    Type: Application
    Filed: October 2, 2013
    Publication date: October 1, 2015
    Inventors: Claire Louise Kulisa, Daniel Christopher Brookings, Daniel James Ford, Richard Jeremy Franklin, James Thomas Reuberson, Anant Ramrao Ghawalkar
  • Therapeutically active thiazolo-pyrimidine derivatives
    Patent number: 9096614
    Abstract: A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: August 4, 2015
    Inventors: Daniel Christopher Brookings, Daniel James Ford, Richard Jeremy Franklin, Anant Ramrao Ghawalkar, Claire Louise Kulisa, Judi Charlotte Neuss, James Thomas Reuberson
  • Therapeutically Active Thiazolo-Pyrimidine Derivatives
    Publication number: 20140315885
    Abstract: A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.
    Type: Application
    Filed: November 8, 2012
    Publication date: October 23, 2014
    Inventors: Daniel Christopher Brookings, Daniel James Ford, Richard Jeremy Franklin, Anant Ramrao Ghawalkar, Claire Louise Kulisa, Judi Charlotte Neuss, James Thomas Reuberson
  • Therapeutically Active Fused Pyrimidine Derivatives
    Publication number: 20140309222
    Abstract: A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.
    Type: Application
    Filed: August 15, 2012
    Publication date: October 16, 2014
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D, UCB PHARMA S.A.
    Inventors: Daniel Christopher Brookings, Daniel James Ford, Anant Ramrao Ghawalkar, Jean Herman, Qiuya Huang, Claire Louise Kulisa, Thierry Louat, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Fused thiazole derivatives as kinase inhibitors
    Patent number: 7888344
    Abstract: A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: February 15, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Rikki Peter Alexander, Pavandeep Aujla, Mark James Batchelor, Daniel Christopher Brookings, George Martin Buckley, Karen Viviane Lucile Crepy, Claire Louise Kulisa, James Petrie Turner
  • Fused Thiazole Derivatives as Kinase Inhibitors
    Publication number: 20080306060
    Abstract: A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: April 25, 2006
    Publication date: December 11, 2008
    Applicant: UCB PHARMA S.A.
    Inventors: Rikki Peter Alexander, Pavandeep Aujla, Mark James Batchelor, Daniel Christopher Brookings, George Martin Buckley, Karen Viviane Lucile Crepy, Claire Louise Kulisa, James Petrie Turner